Month: June 2022

BBS-Bioactive Bone Substitutes Plc, Company Announcement, Insider information, 8 June 2022 2.30 p.m. (CEST) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL. BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 3.5 million The rights issue resolved by BBS-Bioactive Bone Substitutes Plc’s (“BBS” or the “Company”) Board of Directors on 6 May 2022 (the “Offering”) has been subscribed to 77 percent. The Company raised proceeds of approximately EUR 3.5 million from the Offering before deduction of issuance costs and fees. The Board of Directors of the Company resolved on 8 June 2022 to approve the subscriptions received in...

• PBML04 represents the company’s fourth program to receive IND clearance PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PBML04, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of Metachromatic Leukodystrophy (MLD). MLD is a rare, fatal, pediatric, lysosomal storage disease that currently has limited available treatment options. “We are thrilled to have received IND clearance for our program in metachromatic leukodystrophy, marking our fourth IND clearance as a company and our third pediatric lysosomal...

Industry Veteran Brings Nearly Two Decades of Experience in Healthcare Product Management to the Company LEXINGTON, Mass., June 08, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Evan Cox as Vice President of Product Management, effective immediately. In this role, Mr. Cox will manage the growth and future development of the iSpecimen Marketplace™ platform. “Evan’s previous experience in planning, developing and delivering technology solutions for leading healthcare organizations will prove vital as we continue to enhance and expand our Marketplace offering,” said iSpecimen Founder and CEO, Christopher...

CRN04894 Selected for Oral Presentation SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting. Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose cohorts of a Phase 1 study. Results from the company’s Phase 1 study of CRN04777, the company’s investigational candidate for the...

PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi, Cognition’s president and CEO will be presenting an update on the company’s progress developing small-molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. A live and archived webcast can be accessed here as well as on the company’s Events & Presentations webpage.Presentation details:Location: Lotte New York Palace Hotel, Holmes IIDate: Thursday, June 16Time: 12:30 PMAbout Cognition TherapeuticsCognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics...

VANCOUVER, British Columbia, June 08, 2022 (GLOBE NEWSWIRE) — Trailbreaker Resources Ltd. (TBK.V) (“Trailbreaker” or “the Company”) is pleased to announce the completion of its Phase 1 exploration program at their Eakin Creek property in south-central British Columbia (BC). The program was designed to evaluate the known gold showings and to help in de-risking potential future drill programs. Phase 1 consisted of an induced polarization (IP) and resistivity survey, a mobile metal ion (MMI) soil geochemical survey, prospecting and geological reconnaissance. Details of the Phase 1 program (Results pending)11 line-kilometers of deep-penetrating IP and resistivity surveying 90 prospecting grab samples 301 soil samples undergoing MMI analysis, covering a 1.8 x 1.4-kilometre areaAbout Eakin Creek The Eakin Creek property lies in an...

Infographic 1 Infographic 1Infographic 2 Infographic 2Newly Discovered Surebet Zone & New Extension Target Highlights:Fully funded 24,000 meter drilling campaign is underway totaling 85 holes from 24 separate drill pad locations with four diamond drill rigs.The 2022 campaign will include resource level infill drilling as well as targeting the outer extremities of the known gold- silver zone down-dip to trace the extent of this extensive high grade system that remains open.An accompanying infographic is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/cae6ef0e-5738-4184-bf75-7d45fd0847dc 100% of all 24 holes drilled during the 2021 maiden campaign totalling 5,332 meters intersected significant widths of high-grade gold-silver mineralization over 1 km of strike and confirmed 1.1 km of down dip extent:GD-21-03...

SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place in London and online June 22-26. The oral presentation will highlight new dose and duration data from a Phase 2 trial evaluating VIR-2218, an investigational HBV-targeting small interfering ribonucleic acid (siRNA) that mediates RNA interference, for the potential functional cure of chronic HBV infection. One poster presentation will highlight dose-dependent durability data from a Phase 1 trial of VIR-3434, an investigational HBV-neutralizing monoclonal...